DXCM

DXCM

USD

DexCom Inc. Common Stock

$61.180+0.090 (0.147%)

即時價格

Healthcare
醫療器材
美國

價格圖表

Loading Chart...

關鍵指標

市場指標
公司基本面
交易統計

市場指標

開盤

$61.090

最高

$62.390

最低

$58.880

交易量

8.96M

公司基本面

市值

23.9B

行業

醫療器材

國家

United States

交易統計

平均交易量

5.54M

交易所

NMS

貨幣

USD

52週範圍

最低 $56.45當前 $61.180最高 $93.25

AI分析報告

最後更新: 2025年11月4日
由AI生成數據來源: Yahoo Finance, Bloomberg, SEC

DXCM Analysis: DexCom's Rocky Road - Can Recent Bounce Hold?

Market Pulse Check

  • Current Price: $60.43 (as of 2025-11-03 close)
  • Recent Swing: +3.8% rebound after 61% decline since August highs
  • Key Technicals: MACD bearish crossover vs. surging 19x average volume

Price Action Breakdown

  • August-Sept Stability: Traded $75-$82 range
  • Sept 19 Crash: -11% drop on 3x average volume
  • October Freefall: 35% decline accelerated by legal news
  • November Lifeline: +3.8% gain on massive 17.8M shares traded

News Impact Matrix

SentimentCountKey Developments
Negative96 law firm investigations filed
Analyst Mixed128 lowered PTs (range $75-$99)
Positive1New board member appointment

AI Forecast Snapshot

TimeframePredictionNotes
1-day-0.8%Potential pullback after surge
2-day+1.6%Technical rebound potential
3-day+1.9%Resistance near $62 area

Strategic Considerations

For Active Traders:

  • Watch $61.15 breakout level (Nov 3 high)
  • Consider partial profits at $62.90 TP
  • Hard stop below $58.50 support

Long-term Investors:

  • Monitor lawsuit developments closely
  • Debt concerns (94% D/E ratio) require scrutiny
  • Potential accumulation zone if $58 holds

Bottom Line

DexCom's technical bounce faces fundamental headwinds. While AI models suggest near-term upside, the legal overhang creates exceptional risk. The stock needs to reclaim $62 decisively to suggest sustainable recovery. Healthcare sector exposure remains favorable, but DXCM requires tighter risk parameters than peers.


This analysis reflects market conditions as of November 4, 2025. Consider consulting a financial advisor before making investment decisions. Past performance doesn't guarantee future results. Data sources: Analyst reports, SEC filings, market data feeds.

相關新聞

PR Newswire

Stockholder Alert: Robbins LLP Informs Investors of the Dexcom, Inc. Class Action Lawsuit

Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Dexcom, Inc. (NASDAQ:...

查看更多
Stockholder Alert: Robbins LLP Informs Investors of the Dexcom, Inc. Class Action Lawsuit
Analyst Upgrades

UBS Maintains Buy on DexCom, Lowers Price Target to $95

UBS analyst Danielle Antalffy maintains DexCom with a Buy and lowers the price target from $106 to $95.

查看更多
UBS Maintains Buy on DexCom, Lowers Price Target to $95
Analyst Upgrades

Truist Securities Reiterates Buy on DexCom, Lowers Price Target to $82

Truist Securities analyst Richard Newitter reiterates DexCom with a Buy and lowers the price target from $94 to $82.

查看更多
Truist Securities Reiterates Buy on DexCom, Lowers Price Target to $82
Analyst Upgrades

Barclays Maintains Equal-Weight on DexCom, Lowers Price Target to $80

Barclays analyst Matt Miksic maintains DexCom with a Equal-Weight and lowers the price target from $98 to $80.

查看更多
Barclays Maintains Equal-Weight on DexCom, Lowers Price Target to $80
PR Newswire

DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against DexCom, Inc. ("DexCom" or...

查看更多
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm
PR Newswire

DXCM Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against DexCom, Inc. (DXCM) - Contact Kessler Topaz Meltzer & Check, LLP

The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against...

Analyst Upgrades

Wells Fargo Maintains Overweight on DexCom, Lowers Price Target to $93

Wells Fargo analyst Larry Biegelsen maintains DexCom with a Overweight and lowers the price target from $98 to $93.

AI預測Beta

AI推薦

看漲

更新於: 2025年11月4日 下午09:09

看跌中立看漲

60.6% 信心度

風險與交易

風險級別3/5
中等風險
適合
積極保守成長
交易指南

入場點

$58.80

獲利了結

$62.91

止損

$52.39

關鍵因素

DMI 顯示熊市趨勢 (ADX:15.5, +DI:9.8, -DI:18.9),建議謹慎
交易量是平均值 (59,957) 的 19.6 倍,表明極強的買入壓力
MACD -0.1446 在信號線 -0.0199 下方,表示看跌交叉

保持更新

設定價格提醒,獲取AI分析更新和即時市場新聞。